Lupus erythematosus
☆ Na nsonaazụ Stiftung Warentest nke 2022 sitere na Germany, afọ ojuju ndị ahịa na ModelDerm dị ntakịrị ntakịrị karịa na nyocha telemedicine akwụ ụgwọ.
Ọ na-apụta dị ka erythema na-acha odo odo.
Ihe ọkụ ọkụ nru ububa na-apụtakarị na ihu.
References
Ịmata na nkewa cutaneous lupus erythematosus (CLE) na-ebute ihe ịma aka nyocha, na-amata ọdịiche ya na systemic lupus erythematosus na itinye aka na akpụkpọ ahụ. Nnyocha e mere n'oge na-adịbeghị anya mere ka ìhè dị na mkpụrụ ndụ ihe nketa, gburugburu ebe obibi, na ihe mgbochi ọrịa na-akpata CLE. Induction ọgwụ apụtala kpọmkwem dị ka otu n'ime ihe kacha mkpa maka CLE. Ọgwụgwọ na-agụnye usoro ọgwụgwọ n'akụkụ na usoro usoro, gụnyere ihe ndị dị ndụ na-ekwe nkwa (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059) , nke gosipụtara ịdị irè n'ime ule ụlọ ọgwụ.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) na-ekpuchi nsogbu akpụkpọ anụ dị iche iche, ụfọdụ n'ime ha nwere ike jikọta na nsogbu ahụike buru ibu. A na-ekewa ya n'ụdị dị iche iche, dịka acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) . CCLE nwere discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus bụ otu ọrịa autoimmune nke nwere ike imetụta akụkụ ahụ dị iche iche. Ụdị ụfọdụ, dị ka systemic lupus erythematosus (SLE) , na-emetụta ọtụtụ akụkụ ahụ, ebe ndị ọzọ, dị ka cutaneous lupus erythematosus (CLE) , na-emetụtakarị akpụkpọ ahụ. Anyị na-ahazi ụdị CLE dị iche iche dabere na ngwakọta nke akara ụlọ ọgwụ, nyocha anụ ahụ, na nyocha ọbara, mana enwere ọtụtụ mgbanwe n'etiti ndị mmadụ n'otu n'otu. Nsogbu akpụkpọ ahụ na-etolitekarị n'ihi ihe ndị dị ka ikpughe ìhè anyanwụ, ise siga, ma ọ bụ ọgwụ ụfọdụ.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Ihe kpatara lupus erythematosus amabeghị. N'ime ejima ndị yiri ya, ọ bụrụ na otu onye na-emetụta enwere ohere 24% nke ọzọ ga-adịkwa. A kwenyere na homonụ mmekọahụ nke nwanyị, ìhè anyanwụ, ise siga, ụkọ vitamin D, na ọrịa ụfọdụ na-ebutekwa ihe ize ndụ ahụ.
Ọgwụgwọ nwere ike ịgụnye NSAIDs, corticosteroids, immunosuppressants, hydroxychloroquine, na methotrexate. Ọ bụ ezie na corticosteroids dị irè, iji ogologo oge mee ihe na-arụpụta mmetụta dị n'akụkụ.